Cancer chemotherapy in older adults. A tolerability perspective

Drugs and Aging

Volumn 10, Issue 1, 1997, Pages 34-49

  Kimmick, Gretchen G ^a   Fleming, Ronald ^a   Muss, Hyman B ^a   Balducci, Lodovico ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; FLUOROURACIL; METHOTREXATE; MITHRAMYCIN; MITOMYCIN; MITOXANTRONE; NITROSOUREA DERIVATIVE; PACLITAXEL; PROCARBAZINE; SEMUSTINE; VINBLASTINE; VINCA ALKALOID;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARDIOTOXICITY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0031020162     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710010-00004     Document Type: Review

References (100)

1. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986; 255: 3385-90
2. Fentiman IS. Treatment of cancer in the elderly [editorial]. Br J Cancer 1991; 64: 993-5
3. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 1990; 335: 1020-2
4. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer palients. J Am Geriatr Soc 1985; 33: 585-9
5. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986-92
6. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 1980; 3: 369-74
7. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 1992; 268: 57-62
8. Lamy PP. Modifying drug dosage in elderly patients. In: Covington TR, Walker JI, editors. Current geriatric therapy. Philadelphia: W.B. Saunders Company, 1984: 35-72
9. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-10
10. Shaw PG. Common pitfalls in geriatric drug prescribing. Drugs 1982; 23: 324-8
11. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081-8
12. Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing: a practical guide to avoiding problems. Drugs 1989; 37: 105-12
13. Ganz PA. Age and gender as factors in cancer therapy. Clin Geriatr Med 1993; 9: 145-55
14. Ross CE, Mirowsky J. Socially-desirable response and acquiescence in a cross-cultural survey of mental health. J Health Soc Behav 1984; 25: 189-97
15. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580-4
16. Nerenz DR, Love RR, Leventhal H, et al. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res 1986; 20: 961-76
17. Lichtman SM. Physiological aspects of aging: implications for the treatment of cancer. Drugs Aging 1995; 7: 212-25
18. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest: a study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965; 43: 326-31
19. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983; 43: 4467-9
20. McLachlan MS. The ageing kidney. Lancet 1978; II: 143-5
21. Cockcroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-42
22. Chabner B. Clinical strategies for cancer treatment: the role of drugs. In: Chabner B, Collins J, editors. Cancer chemotherapy: principles and practice. Philadelphia: J.B. Lippincott, 1990: 1-15
23. Lipschitz DA, Udupa KB. Age and the hematopoietic system. J Am Geriatr Soc 1986; 34: 448-54
24. Baime MJ, Nelson JB, Castell DO. Aging of the gastrointestinal system. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 665-81
25. Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192-8
26. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303-9
27. Geokas MC, Lakatta EG, Makinodan T, et al. The aging process. Ann Intern Med 1990; 113: 455-66
28. Maloney AG, Schumucker DL, Vessey DS. The effects of aging on the hepatic microsomal mixed-function oxidase system of male and female monkeys. Hepatology 1986; 6: 282-7
29. Powis G. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev 1982; 9: 85-124
30. Terry LC, Halter JB. Aging of the endocrine system. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 791-806
31. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63
32. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic deregulation? Blood 1993; 82: 2601-4
33. Mayersohn M. Special pharmacokinetic considerations in the elderly. In: Evans WE. editor. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Vancouver: Applied Therapeutics, 1986: 244-6
34. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29: 201-5
35. Moore JG, Tweedy C, Christian PE, et al. Effect of age on gastric emptying of liquid-solid meals in man. Dig Dis Sci 1983; 28: 340-4
36. Popper H. Aging and the liver. Prog Liver Dis 1986; 8: 659-83
37. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow: the influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 287-94
38. Balducci L, Mowrey K, Parker M. Pharmacology of antineoplastic agents in older patients. In: Balducci L, Lyman GH, Ershler WB, editors. Geriatric oncology. Philadelphia: J.B. Lippincott, 1992: 169-80
39. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76-84
40. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7
41. Poirier J, Finch CE. Neurochemistry of the aging human brain. In: Hazzard WR, Bierman EL, Blass JP, et al., editors. Principles of geriatric medicine and gerontology. 3rd ed. New York: McGraw-Hill, 1994: 1005-12
42. Brandstetter RD, Kazemi H. Aging and the respiratory system. Med Clin North Am 1983; 67: 419-31
43. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979; 27: 20-2
44. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493-6
45. Moscow JA, Schneider E, Cowan KH. Multidrug resistance. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. Annual 16. Amsterdam: Elsevier Science BV, 1996: 111-31
46. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia 1996; 10 Suppl. 1: S33-5
47. Rockwell O, Hughes CS, Kennedy KA. Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. Int J Rad Oncol Biol Phys 1991; 20: 259-63
48. Reed JC. BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 1995; 9: 450-73
49. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305
50. Peterson BA, Pajak TF, Cooper MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889-98
51. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404-13
52. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56
53. 51Cr-EDTA. Clin Sci 1969; 37 (i): 169-80
54. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother Pharmacol 1988; 23: 163-7
55. Shank Jr WA, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151-4
56. Chatta GS, Price TH, Allen RC, et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923-9
57. Vose JM. Cytokine use in the older patient. Semin Oncol 1995; 22 (1 Suppl. 1): 6-8
58. Petrelli N, Douglass Jr HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-26 [published erratum appears in J Clin Oncol 1990 Jan; 8(1): 185]
59. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 1995; 75: 11-7
60. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992; 6: 62-8
61. Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52: 51-60
62. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986; 58: 607-13
63. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37-45
64. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-86
65. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52
66. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995; 7: 304-9
67. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-71
68. Fountzilas G, Afthonidis D, Geleris P, et al. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer. Anticancer Res 1992; 12: 231-4
69. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611-20
70. Bennett JM, Byrne P, Desai A, et al. A randomized multicenter trial of cyclophosphamide. Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide. Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Invest New Drugs 1985; 3: 179-85
71. Pouillart P, Follezou JY, Palangie T, et al. Long-term results of u randomised trial comparing regimens of cyclophosphamide und fluorouracil with either mitoxantrone or doxorubicin in patients with advanced breast cancer. Eur J Cancer 1994; 30A: 715-6
72. Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996; 9 (2): 122-47
73. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53: 3028-33
74. Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-10
75. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509-14
76. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-6
77. Ensley JF, Patel B, Kloner R, et al. The clinical syndrome of 5-fluorouracil Cardiotoxicity. Invest New Drugs 1989; 7: 101-9
78. Haas CD, Coltman CA, Gottlieb JA, et al. Phase II evaluation of bleomycin: a Southwest Oncology Group study. Cancer 1976; 38: 8-12
79. Crooke ST, Comis RL, Einhorn LH, et al. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treat Rep 1977; 61: 1631-6
80. Hrushesky WJ, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76: 579-84
81. Sella A, Logothetis CJ, Dexeus FH, et al. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 1991; 67: 603-7
82. Raghavan D, Grundy R, Greenaway TM, et al. Pre-emptive (neoadjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer: age itself is not a contra-indication. Br J Urol 1988; 62 (2): 154-9
83. Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin for elderly patients. Age Ageing 1992; 21: 202-4
84. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121-5
85. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21 Suppl. 11: 8-15
86. van der Vijgh WJF, Peters GJ. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin Oncol 1994; 21 Suppl. 11: 2-7
87. Glick J, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
88. Gottlieb D, Bradstock K, Koutts J, et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987; 60: 1439-41
89. Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989; 7: 1563-8
90. Rosenthal SM, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974; 80: 733-7
91. Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84: 1016-22
92. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975; 36: 409-14
93. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981; 19: 443-51
94. Kristensen LO, Weismann K, Hutters L. Renal function and the rale of disappearance of methotrexate from serum. Eur J Clin Pharmacol 1975; 8: 439-44
95. Cadman EC, Lundberg WB, Bertino JR. Systemic methotrexate toxicity: a pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. Arch Intern Med 1976; 136: 1321-2
96. Milano G, Etienne MC, Cassuto-Vigurier E. Influence of age and sex on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-5
97. McLeod BF, Lawrence HJ, Smith DW, et al. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 1987; 60: 2617-20
98. Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin Pharm 1989; 8: 274-93
99. Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34: 576-83
100. Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kid Dis 1983; 3: 155-80